DailyIQ
Last updatedjust now

HIMS·Hims & Hers Health, Inc.

$27.73
-0.09 (-0.32%)
Overnight$27.75+0.02 (+0.07%)
High
$28.13
Open
$27.73
Market Cap
6.49B
52W High
$65.30
Low
$27.38
P. Close
$27.73
P/E
50.56
52W Low
$13.74
Fwd P/E
36.28
DailyIQ Est.
$31.64
Inst. Ownership
68.2%
Short Interest
25.09%
Days to Cover
4.5
Technical Score (1D)
5
SELL
News Sentiment
73
BULLISH
Hims & Hers’ launch in Australia, achieved through the acquisition of Eucalyptus, marks the company’s first Asia‑Pacific expansion and is expected to add a 21 % YoY lift in revenue per subscriber, signalling a new growth engine that could offset margin pressure from the U.S. weight‑loss line. The move also positions Hims to tap a $2.56 B telehealth market projected to reach by 2034, potentially accelerating international revenue to $131 M and bringing the total subscriber base closer to three million. Meanwhile, the firm’s Q2 results still show a 38‑40 % jump in revenue to $753 M and a higher full‑year forecast, underscoring the upside that the Australian entry may help sustain over the next 1–10 trading days. However, the company remains under scrutiny from the FTC for alleged data‑sharing violations and from Visa for a high credit‑card dispute rate, both of which could trigger regulatory fines or cost‑additions that erode margins. The FTC lawsuit, which the CEO argues misreads Hims’ model, could lead to enforcement actions that would require costly compliance changes or settlements, adding uncertainty to the company’s valuation. Visa’s Acquirer Monitoring Program imposes an $8 surcharge per disputed transaction, potentially adding a new cost layer that could dampen the profitability of the subscription‑based weight‑loss business. Investors should watch the FTC’s next filing for any settlement or ruling, as well as Visa’s monitoring status, to gauge the risk of additional regulatory or cost headwinds. Finally, the company’s planned expansion into AI‑driven healthcare tools and experimental peptide therapies could provide a longer‑term growth catalyst, but only if it can navigate the current legal and billing challenges without significant operational disruption.
Earnings Summary
Hims & Hers Health, Inc. (HIMS) operates a telehealth platform that delivers prescription medications and health products directly to consumers, with a focus on sexual health, skincare, hair care, and wellness products, complemented by a Labs service for personalized health insights. In the last two quarters, HIMS’s EPS fell from $0.06 in Q3 2025 to a loss of $0.10 in Q2 2026, while revenue rose from $598.976 million to $753.21 million, reflecting a 25% YoY revenue increase but a decline in profitability; the company beat estimates in Q1 2025 and Q2 2025 but missed in Q3 2025 and Q4 2025, with EPS falling below forecasts in the latter two quarters. Historically, HIMS has experienced volatile earnings, with periods of strong revenue growth offset by margin compression and occasional losses, yet it has maintained a pattern of revenue acceleration driven by its weight‑loss product line. Recent news highlights regulatory headwinds: Visa’s placement of HIMS on its Acquirer Monitoring Program adds an $8 surcharge per disputed transaction, and the FTC and state regulators have filed a civil enforcement action alleging telehealth privacy and subscription violations; these developments could erode subscription‑based margins and increase operating costs. Investors should watch for guidance on dispute‑rate reductions required to exit Visa’s program, any progress on the FTC enforcement action, and the trajectory of gross margins as the company expands its testosterone and peptide lines, which could offset margin pressure if the new product mix delivers higher gross margins.

EPS

EstBeatMiss
$-0.24$-0.10$0.03$0.17$0.31Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.16 - -
Q2'26$0.11$-0.10-187.1%
Q1'26$0.13$-0.18-235.8%
Q4'25$0.25$0.07-71.9%
Q3'25$0.10$0.06-41.0%
Q2'25$0.16$0.17+3.2%

Revenue

EstBeatMiss
$490M$609M$728M$847M$967MQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$912M - -
Q2'26$714M$753M+5.5%
Q1'26$629M$608M-3.4%
Q4'25$653M$618M-5.3%
Q3'25 - $599M -
Q2'25 - $545M -

Market Data

HIMS Stock Snapshot

SELL5/100
$27.75+$0.02 (0.1%)
Market cap
6.49B
P/E ratio
50.6
Day range
$27.38 – $28.13
News sentiment
73/100 · Bullish
Analyst target
$31.23 (+12.5%)
Consensus
Hold · 24 analysts
52-week range+102.0% off low · -57.5% from high
$13.74$65.30
Price $27.75 DailyIQ Est. $31.64

Price action on HIMS is defensive - rallies are being sold rather than extended. At this size, a single catalyst moves the stock further than it would a larger peer.

Behaviour On Record

What HIMS's own history says about today's numbers

Realized volatility (21d)
80.1% 68th pct
Below its peak
-59.2%
vs 200-day average
-1.3%
Up days (1y)
48%

Hims & Hers Health, Inc. is currently running 80.1% annualised volatility over the last 21 sessions. Measured against HIMS's own 7 years of daily returns rather than a market-wide average, that is the 68th percentile a little above its own norm, against a typical reading of 68.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

HIMS is trading -59.2% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -52.7%, and the deepest was -77.1% in 2021. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -1.3% from its 200-day moving average. Against every other day in its history, that gap ranks at the 39th percentile close to the gap it normally carries. Over the past year HIMS closed higher on 48% of sessions, and it is currently 1 session into a rising streak.

On September specifically: over 6 years of records, HIMS finished the month higher 3 of 6 times, with a median return of +2.0% and an average of +8.2%. Its strongest month historically has been November at +16.0% on average, its weakest August at -11.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: HIMS has opened more than 2% away from the prior close in 268 of 1,691 sessions (15.8% of the time), with the largest gaps running +14.4% and -8.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, HIMS moved an average of 4.3% in the session after earnings, closing higher 2 of those 3 times, with a median move of +2.9% and a largest of +8.5%.

All figures computed from 1,692 daily closes between 2019-09-13 and 2026-09-04, split-adjusted, recomputed daily. Percentiles are against HIMS's own 7-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of HIMS's sector?

Hims & Hers Health, Inc. sits in the Health Care sector, currently ranked 2nd of 11 GICS sectors by relative-strength rotation score (weakening).

Sector rank
#2 of 11
Sector state
Weakening
Sector rotation score
90

Options Market

What is the options market pricing for HIMS?

CallsPuts

For Hims & Hers Health, Inc.'s nearest expiry (2026-09-11, 14 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.40), with at-the-money implied volatility around 59.4%. The options market is pricing roughly a ±11.2% move by that expiry — a range of about $24.64–$30.86.

Put/call ratio (2026-09-11)
0.40
ATM implied volatility
59.4%
Total open interest
41,565
Expected move by 2026-09-11
±11.2% ($24.64–$30.86)

HIMS Competitive Positioning

Hims & Hers Health, Inc. (HIMS) is tracked alongside these names in Drug Manufacturers - Specialty & Generic on DailyIQ — ranked by market cap, with today's move alongside.